Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): A randomized trial.

Angela Yee-Moon WangWai Kei LoStephen Chi-Wai CheungTak-Ka TangYat-Yin YauBrian Hung-Hin Lang

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)

Both cinacalcet and PTx effectively improved various biochemical abnormalities of CKD-MBD and stabilized but did not reduce LV mass, coronary artery and heart valves calcification, arterial stiffness or improve patient-centered HRQOL measures in PD patients with advanced SHPT. Cinacalcet may be used in place of PTx for treating advanced SHPT. Long-term and powered studies are required to evaluate PTx versus cinacalcet on hard cardiovascular outcomes in dialysis patients.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
coronary artery
heart failure
blood pressure
pulmonary artery
ejection fraction
aortic valve
coronary artery disease
newly diagnosed
atrial fibrillation
pulmonary arterial hypertension
prognostic factors
patient reported
aortic stenosis